Edition:
United States

Hemispherx Biopharma Inc (HEB.A)

HEB.A on American Stock Exchange

0.49USD
21 Feb 2017
Change (% chg)

$0.03 (+6.53%)
Prev Close
$0.46
Open
$0.46
Day's High
$0.51
Day's Low
$0.46
Volume
17,325
Avg. Vol
15,480
52-wk High
$2.63
52-wk Low
$0.40

Select another date:

Thu, Jan 26 2017

BRIEF-Hemispherx Biopharma says order of newly manufactured Rintatolimod has been shipped

* Hemispherx Biopharma Inc says order of newly manufactured Rintatolimod for sale utilizing early access program in Europe has been shipped Source text for Eikon: Further company coverage:

BRIEF-Hemispherx Biopharma enters into purchase order with Jubilant Hollister Stier

* Hemispherx Biopharma- On Jan. 3, entered into purchase order with Jubilant Hollister Stier, where Jubilant will manufacture commercial batch of Ampligen for co Source: (http://bit.ly/2ju230U) Further company coverage:

BRIEF-Hemispherx Biopharma announces extension of Rintatolimod European early access program

* Hemispherx Biopharma announces extension of Rintatolimod European early access program (eap) to pancreatic cancer patients Source text for Eikon: Further company coverage:

BRIEF-Frigate Ventures reports 6.9 pct passive stake in Hemispherx Biopharma

* Frigate Ventures Lp reports 6.9 pct passive stake in Hemispherx Biopharma Inc as of August 31, 2016 - SEC filing Source text: (http://bit.ly/2cATyOR) Further company coverage:

BRIEF-Sabby Management LLC reports 6.92 pct passive stake in Hemispherx Biopharma

* Sabby Management LLC reports 6.92 percent passive stake in Hemispherx Biopharma Inc as of August 31 - Sec Filing Source text : http://bit.ly/2bFyk25 Further company coverage:

BRIEF-Hemispherx Biopharma announces $5 mln registered direct offering

* Hemispherx Biopharma Inc announces $5 million registered direct offering

BRIEF-Hemispherx Biopharma received approval of its new drug application from ANMAT

* Received approval of its new drug application from anmat for commercial sale of rintatolimod in argentine republic

BRIEF-Hemispherx Biopharma gets approval of NDA to treat chronic fatigue syndrome

* Received approval of NDA in argentine republic for treatment of severe myalgic encephalomyelitis/chronic fatigue syndrome

Select another date:

More From Around the Web